Viridian Therapeutics
VRDN
9 hedge funds and large institutions have $1.22M invested in Viridian Therapeutics in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.
7% less capital invested
Capital invested by funds: $1.32M → $1.22M (-$96.6K)
10% less funds holding
Funds holding: 10 → 9 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$113K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$54.3K |
| 3 |
SGH
Schonfeld Group Holdings
Jericho,
New York
|
+$19.8K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$17.8K |
| 5 |
FNYS
First New York Securities
New York
|
+$8.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$153K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$56K |
| 3 |
WPC
White Pine Capital
Bloomington,
Minnesota
|
-$51K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
1
Perkins Capital Management
Wayzata,
Minnesota
| $446K | -$10.1K | -25 | -3% |
|
|
HA
2
Heartland Advisors
Milwaukee,
Wisconsin
| $252K | -$153K | -378 | -43% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $235K | +$54.3K | +134 | +39% |
|
|
4
Barclays
London,
United Kingdom
| $126K | +$113K | +280 | New |
|
5
Bank of America
Charlotte,
North Carolina
| $106K | – | – | – |
|
|
SGH
6
Schonfeld Group Holdings
Jericho,
New York
| $24K | +$19.8K | +49 | New |
|
|
7
Creative Planning
Overland Park,
Kansas
| $22K | +$17.8K | +44 | New |
|
|
FNYS
8
First New York Securities
New York
| $9.86K | +$8.1K | +20 | New |
|
|
AIG
9
American International Group
New York
| $548 | +$405 | +1 | New |
|
|
VKH
10
Virtu KCG Holdings
New York
| – | -$56K | -117 | Closed |
|
|
WPC
11
White Pine Capital
Bloomington,
Minnesota
| – | -$51K | -106 | Closed |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$34K | -69 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$17K | -36 | Closed |
|
14
UBS Group
Zurich,
Switzerland
| – | -$8K | -17 | Closed |
|
15
Citigroup
New York
| – | -$3K | -6 | Closed |
|
VRDN Hedge Fund Activity: Q2 2015 in Review
9 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2015, worth a combined $1.22M — down 7.3% from $1.32M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VRDN and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Barclays, opening a new position worth an estimated $113K. The largest seller was Heartland Advisors, cutting an estimated $153K.
- 9 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2015, down from 10 in Q1 2015.
- Funds reported $1.22M of Viridian Therapeutics stock for Q2 2015, down 7.3% quarter-over-quarter.
- 5 funds opened new Viridian Therapeutics positions in Q2 2015 and 6 closed out, a net change of -1 holder.
- The largest Viridian Therapeutics buyer in Q2 2015 was Barclays, an estimated $113K added.
- The largest Viridian Therapeutics seller in Q2 2015 was Heartland Advisors, an estimated $153K sold.
Based on aggregated 13F filings for Q2 2015.